<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37189338</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2218-273X</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Mar</Month><Day>25</Day></PubDate></JournalIssue><Title>Biomolecules</Title><ISOAbbreviation>Biomolecules</ISOAbbreviation></Journal><ArticleTitle>Functional Genome Analysis for Immune Cells Provides Clues for Stratification of Systemic Lupus Erythematosus.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">591</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/biom13040591</ELocationID><Abstract><AbstractText>Systemic lupus erythematosus (SLE) is caused by a combination of genetic and environmental factors. Recently, analysis of a functional genome database of genetic polymorphisms and transcriptomic data from various immune cell subsets revealed the importance of the oxidative phosphorylation (OXPHOS) pathway in the pathogenesis of SLE. In particular, activation of the OXPHOS pathway is persistent in inactive SLE, and this activation is associated with organ damage. The finding that hydroxychloroquine (HCQ), which improves the prognosis of SLE, targets toll-like receptor (TLR) signaling upstream of OXPHOS suggests the clinical importance of this pathway. IRF5 and SLC15A4, which are regulated by polymorphisms associated with SLE susceptibility, are functionally associated with OXPHOS as well as blood interferon activity and metabolome. Future analyses of OXPHOS-associated disease-susceptibility polymorphisms, gene expression, and protein function may be useful for risk stratification of SLE.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fujio</LastName><ForeName>Keishi</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-7276-5254</Identifier><AffiliationInfo><Affiliation>Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Biomolecules</MedlineTA><NlmUniqueID>101596414</NlmUniqueID><ISSNLinking>2218-273X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9008-11-1</RegistryNumber><NameOfSubstance UI="D007372">Interferons</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051193">Toll-Like Receptors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007372" MajorTopicYN="N">Interferons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051193" MajorTopicYN="N">Toll-Like Receptors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">B cell</Keyword><Keyword MajorTopicYN="N">OXPHOS</Keyword><Keyword MajorTopicYN="N">functional genome analysis</Keyword><Keyword MajorTopicYN="N">genome wide association study</Keyword><Keyword MajorTopicYN="N">prognosis</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>16</Day><Hour>1</Hour><Minute>8</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37189338</ArticleId><ArticleId IdType="pmc">PMC10136231</ArticleId><ArticleId IdType="doi">10.3390/biom13040591</ArticleId><ArticleId IdType="pii">biom13040591</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kaul A., Gordon C., Crow M.K., Touma Z., Urowitz M.B., van Vollenhoven R., Ruiz-Irastorza G., Hughes G. Systemic lupus erythematosus. Nat. Rev. Dis. Prim. 2016;2:16039. doi: 10.1038/nrdp.2016.39.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2016.39</ArticleId><ArticleId IdType="pubmed">27306639</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanouriakis A., Tziolos N., Bertsias G., Boumpas D.T. Update omicronn the diagnosis and management of systemic lupus erythematosus. Ann. Rheum. Dis. 2021;80:14&#x2013;25. doi: 10.1136/annrheumdis-2020-218272.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-218272</ArticleId><ArticleId IdType="pubmed">33051219</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas G., Mancini J., Jourde-Chiche N., Sarlon G., Amoura Z., Harle J.R., Jougla E., Chiche L. Mortality associated with systemic lupus erythematosus in France assessed by multiple-cause-of-death analysis. Arthritis Rheumatol. 2014;66:2503&#x2013;2511. doi: 10.1002/art.38731.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.38731</ArticleId><ArticleId IdType="pubmed">24910304</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartels C.M., Buhr K.A., Goldberg J.W., Bell C.L., Visekruna M., Nekkanti S., Greenlee R.T. Mortality and cardiovascular burden of systemic lupus erythematosus in a US population-based cohort. J. Rheumatol. 2014;41:680&#x2013;687. doi: 10.3899/jrheum.130874.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.130874</ArticleId><ArticleId IdType="pmc">PMC3975689</ArticleId><ArticleId IdType="pubmed">24532834</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatto M., Zen M., Iaccarino L., Doria A. New therapeutic strategies in systemic lupus erythematosus management. Nat. Rev. Rheumatol. 2019;15:30&#x2013;48. doi: 10.1038/s41584-018-0133-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-018-0133-2</ArticleId><ArticleId IdType="pubmed">30538302</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathian A., Pha M., Haroche J., Cohen-Aubart F., Hie M., Pineton de Chambrun M., Boutin T.H.D., Miyara M., Gorochov G., Yssel H., et al. Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: A randomised clinical trial. Ann. Rheum. Dis. 2020;79:339&#x2013;346. doi: 10.1136/annrheumdis-2019-216303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2019-216303</ArticleId><ArticleId IdType="pubmed">31852672</ArticleId></ArticleIdList></Reference><Reference><Citation>Elkon K.B., Briggs T.A. The (Orf)ull truth about IRF5 and type I interferons in SLE. Nat. Rev. Rheumatol. 2020;16:543&#x2013;544. doi: 10.1038/s41584-020-0472-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-020-0472-7</ArticleId><ArticleId IdType="pubmed">32709997</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka Y., Kusuda M., Yamaguchi Y. Interferons and systemic lupus erythematosus: Pathogenesis, clinical features and treatments in interferon-driven disease. Mod. Rheumatol. 2022 doi: 10.1093/mr/roac140. ahead of print .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/mr/roac140</ArticleId><ArticleId IdType="pubmed">36440704</ArticleId></ArticleIdList></Reference><Reference><Citation>Wigerblad G., Kaplan M.J. Neutrophil extracellular traps in systemic autoimmune and autoinflammatory diseases. Nat. Rev. Immunol. 2022:1&#x2013;15. doi: 10.1038/s41577-022-00787-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-022-00787-0</ArticleId><ArticleId IdType="pmc">PMC9579530</ArticleId><ArticleId IdType="pubmed">36257987</ArticleId></ArticleIdList></Reference><Reference><Citation>Bocharnikov A.V., Keegan J., Wacleche V.S., Cao Y., Fonseka C.Y., Wang G., Muise E.S., Zhang K.X., Arazi A., Keras G., et al. PD-1hiCXCR5- T peripheral helper cells promote B cell responses in lupus via MAF and IL-21. JCI Insight. 2019;4:e130062. doi: 10.1172/jci.insight.130062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.130062</ArticleId><ArticleId IdType="pmc">PMC6824311</ArticleId><ArticleId IdType="pubmed">31536480</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeshima Y., Iwasaki Y., Nakano M., Narushima Y., Ota M., Nagafuchi Y., Sumitomo S., Okamura T., Elkon K., Ishigaki K., et al. Immune cell multiomics analysis reveals contribution of oxidative phosphorylation to B-cell functions and organ damage of lupus. Ann. Rheum. Dis. 2022;81:845&#x2013;853. doi: 10.1136/annrheumdis-2021-221464.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221464</ArticleId><ArticleId IdType="pubmed">35236659</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherlinger M., Tsokos G.C. Reactive oxygen species: The Yin and Yang in (auto-)immunity. Autoimmun. Rev. 2021;20:102869. doi: 10.1016/j.autrev.2021.102869.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2021.102869</ArticleId><ArticleId IdType="pubmed">34118461</ArticleId></ArticleIdList></Reference><Reference><Citation>Hisada R., Yoshida N., Orite S.Y.K., Umeda M., Burbano C., Scherlinger M., Kono M., Krishfield S., Tsokos G.C. Role of Glutaminase 2 in Promoting CD4+ T Cell Production of Interleukin-2 by Supporting Antioxidant Defense in Systemic Lupus Erythematosus. Arthritis Rheumatol. 2022;74:1204&#x2013;1210. doi: 10.1002/art.42112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.42112</ArticleId><ArticleId IdType="pubmed">35254008</ArticleId></ArticleIdList></Reference><Reference><Citation>Sul J.H., Raj T., de Jong S., de Bakker P.I., Raychaudhuri S., Ophoff R.A., Stranger B.E., Eskin E., Han B. Accurate and fast multiple-testing correction in eQTL studies. Am. J. Hum. Genet. 2015;96:857&#x2013;868. doi: 10.1016/j.ajhg.2015.04.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2015.04.012</ArticleId><ArticleId IdType="pmc">PMC4457958</ArticleId><ArticleId IdType="pubmed">26027500</ArticleId></ArticleIdList></Reference><Reference><Citation>Khera A.V., Chaffin M., Aragam K.G., Haas M.E., Roselli C., Choi S.H., Natarajan P., Lander E.S., Lubitz S.A., Ellinor P.T., et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat. Genet. 2018;50:1219&#x2013;1224. doi: 10.1038/s41588-018-0183-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-018-0183-z</ArticleId><ArticleId IdType="pmc">PMC6128408</ArticleId><ArticleId IdType="pubmed">30104762</ArticleId></ArticleIdList></Reference><Reference><Citation>Marigorta U.M., Denson L.A., Hyams J.S., Mondal K., Prince J., Walters T.D., Griffiths A., Noe J.D., Crandall W.V., Rosh J.R., et al. Transcriptional risk scores link GWAS to eQTLs and predict complications in Crohn&#x2019;s disease. Nat. Genet. 2017;49:1517&#x2013;1521. doi: 10.1038/ng.3936.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3936</ArticleId><ArticleId IdType="pmc">PMC5745037</ArticleId><ArticleId IdType="pubmed">28805827</ArticleId></ArticleIdList></Reference><Reference><Citation>Buniello A., MacArthur J.A.L., Cerezo M., Harris L.W., Hayhurst J., Malangone C., McMahon A., Morales J., Mountjoy E., Sollis E., et al. The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. Nucleic. Acids Res. 2019;47:D1005&#x2013;D1012. doi: 10.1093/nar/gky1120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gky1120</ArticleId><ArticleId IdType="pmc">PMC6323933</ArticleId><ArticleId IdType="pubmed">30445434</ArticleId></ArticleIdList></Reference><Reference><Citation>Farh K.K., Marson A., Zhu J., Kleinewietfeld M., Housley W.J., Beik S., Shoresh N., Whitton H., Ryan R.J., Shishkin A.A., et al. Genetic and epigenetic fine mapping of causal autoimmune disease variants. Nature. 2015;518:337&#x2013;343. doi: 10.1038/nature13835.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature13835</ArticleId><ArticleId IdType="pmc">PMC4336207</ArticleId><ArticleId IdType="pubmed">25363779</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishigaki K., Kochi Y., Suzuki A., Tsuchida Y., Tsuchiya H., Sumitomo S., Yamaguchi K., Nagafuchi Y., Nakachi S., Kato R., et al. Polygenic burdens on cell-specific pathways underlie the risk of rheumatoid arthritis. Nat. Genet. 2017;49:1120&#x2013;1125. doi: 10.1038/ng.3885.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3885</ArticleId><ArticleId IdType="pubmed">28553958</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmiedel B.J., Singh D., Madrigal A., Valdovino-Gonzalez A.G., White B.M., Zapardiel-Gonzalo J., Ha B., Altay G., Greenbaum J.A., McVicker G., et al. Impact of Genetic Polymorphisms on Human Immune Cell Gene Expression. Cell. 2018;175:1701&#x2013;1715.e16. doi: 10.1016/j.cell.2018.10.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.10.022</ArticleId><ArticleId IdType="pmc">PMC6289654</ArticleId><ArticleId IdType="pubmed">30449622</ArticleId></ArticleIdList></Reference><Reference><Citation>Ota M., Nagafuchi Y., Hatano H., Ishigaki K., Terao C., Takeshima Y., Yanaoka H., Kobayashi S., Okubo M., Shirai H., et al. Dynamic landscape of immune cell-specific gene regulation in immune-mediated diseases. Cell. 2021;184:3006&#x2013;3021.e17. doi: 10.1016/j.cell.2021.03.056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.03.056</ArticleId><ArticleId IdType="pubmed">33930287</ArticleId></ArticleIdList></Reference><Reference><Citation>Bentham J., Morris D.L., Graham D.S.C., Pinder C.L., Tombleson P., Behrens T.W., Martin J., Fairfax B.P., Knight J.C., Chen L., et al. Genetic association analyses implicate aberrant regulation of innate and adaptive immunity genes in the pathogenesis of systemic lupus erythematosus. Nat. Genet. 2015;47:1457&#x2013;1464. doi: 10.1038/ng.3434.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3434</ArticleId><ArticleId IdType="pmc">PMC4668589</ArticleId><ArticleId IdType="pubmed">26502338</ArticleId></ArticleIdList></Reference><Reference><Citation>Tektonidou M.G., Lewandowski L.B., Hu J., Dasgupta A., Ward M.M. Survival in adults and children with systemic lupus erythematosus: A systematic review and Bayesian meta-analysis of studies from 1950 to 2016. Ann. Rheum. Dis. 2017;76:2009&#x2013;2016. doi: 10.1136/annrheumdis-2017-211663.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2017-211663</ArticleId><ArticleId IdType="pubmed">28794077</ArticleId></ArticleIdList></Reference><Reference><Citation>Bultink I.E.M., de Vries F., van Vollenhoven R.F., Lalmohamed A. Mortality, causes of death and influence of medication use in patients with systemic lupus erythematosus vs matched controls. Rheumatology. 2021;60:207&#x2013;216. doi: 10.1093/rheumatology/keaa267.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keaa267</ArticleId><ArticleId IdType="pmc">PMC8312724</ArticleId><ArticleId IdType="pubmed">32653901</ArticleId></ArticleIdList></Reference><Reference><Citation>Zen M., Iaccarino L., Gatto M., Bettio S., Saccon F., Ghirardello A., Punzi L., Doria A. The effect of different durations of remission on damage accrual: Results from a prospective monocentric cohort of Caucasian patients. Ann. Rheum. Dis. 2017;76:562&#x2013;565. doi: 10.1136/annrheumdis-2016-210154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2016-210154</ArticleId><ArticleId IdType="pubmed">27884821</ArticleId></ArticleIdList></Reference><Reference><Citation>Sumikawa M.H., Iwata S., Zhang M., Miyata H., Ueno M., Todoroki Y., Nagayasu A., Kanda R., Sonomoto K., Torimoto K., et al. An enhanced mitochondrial function through glutamine metabolism in plasmablast differentiation in systemic lupus erythematosus. Rheumatology. 2022;61:3049&#x2013;3059. doi: 10.1093/rheumatology/keab824.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keab824</ArticleId><ArticleId IdType="pubmed">34730825</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanouriakis A., Kostopoulou M., Alunno A., Aringer M., Bajema I., Boletis J.N., Cervera R., Doria A., Gordon C., Govoni M., et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann. Rheum. Dis. 2019;78:736&#x2013;745. doi: 10.1136/annrheumdis-2019-215089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2019-215089</ArticleId><ArticleId IdType="pubmed">30926722</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi T., Nguyen-Tien D., Ohshima D., Karyu H., Shimabukuro-Demoto S., Yoshida-Sugitani R., Toyama-Sorimachi N. Human SLC15A4 is crucial for TLR-mediated type I interferon production and mitochondrial integrity. Int. Immunol. 2021;33:399&#x2013;406. doi: 10.1093/intimm/dxab006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/intimm/dxab006</ArticleId><ArticleId IdType="pubmed">33560415</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiesel F.C., Moussaud-Lamodiere E.L., Ando M., Springer W. A specific subset of E2 ubiquitin-conjugating enzymes regulate Parkin activation and mitophagy differently. J. Cell Sci. 2014;127:3488&#x2013;3504. doi: 10.1242/jcs.147520.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.147520</ArticleId><ArticleId IdType="pmc">PMC4132391</ArticleId><ArticleId IdType="pubmed">24928900</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuart J.M., Segal E., Koller D., Kim S.K. A gene-coexpression network for global discovery of conserved genetic modules. Science. 2003;302:249&#x2013;255. doi: 10.1126/science.1087447.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1087447</ArticleId><ArticleId IdType="pubmed">12934013</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi Z., Keung K.L., Li L., Hu M., Lu B., Nicholson L., Jimenez-Vera E., Menon M.C., Wei C., Alexander S., et al. Key driver genes as potential therapeutic targets in renal allograft rejection. JCI Insight. 2020;5:e136220. doi: 10.1172/jci.insight.136220.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.136220</ArticleId><ArticleId IdType="pmc">PMC7455082</ArticleId><ArticleId IdType="pubmed">32634125</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang D., Song Y., Wang X., Sun J., Ben Y., An X., Tong L., Bi J., Wang X., Bai C. Deletion of peroxiredoxin 6 potentiates lipopolysaccharide-induced acute lung injury in mice. Crit. Care Med. 2011;39:756&#x2013;764. doi: 10.1097/CCM.0b013e318206befd.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e318206befd</ArticleId><ArticleId IdType="pubmed">21200322</ArticleId></ArticleIdList></Reference><Reference><Citation>Banchereau R., Hong S., Cantarel B., Baldwin N., Baisch J., Edens M., Cepika A.M., Acs P., Turner J., Anguiano E., et al. Personalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus Patients. Cell. 2016;165:551&#x2013;565. doi: 10.1016/j.cell.2016.03.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2016.03.008</ArticleId><ArticleId IdType="pmc">PMC5426482</ArticleId><ArticleId IdType="pubmed">27040498</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez R.K., Gordon M.G., Subramaniam M., Kim M.C., Hartoularos G.C., Targ S., Sun Y., Ogorodnikov A., Bueno R., Lu A., et al. Single-cell RNA-seq reveals cell type-specific molecular and genetic associations to lupus. Science. 2022;376:eabf1970. doi: 10.1126/science.abf1970.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abf1970</ArticleId><ArticleId IdType="pmc">PMC9297655</ArticleId><ArticleId IdType="pubmed">35389781</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakano M., Ota M., Takeshima Y., Iwasaki Y., Hatano H., Nagafuchi Y., Itamiya T., Maeda J., Yoshida R., Yamada S., et al. Distinct transcriptome architectures underlying lupus establishment and exacerbation. Cell. 2022;185:3375&#x2013;3389.e21. doi: 10.1016/j.cell.2022.07.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.07.021</ArticleId><ArticleId IdType="pubmed">35998627</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi T., Shimabukuro-Demoto S., Yoshida-Sugitani R., Furuyama-Tanaka K., Karyu H., Sugiura Y., Shimizu Y., Hosaka T., Goto M., Kato N., et al. The histidine transporter SLC15A4 coordinates mTOR-dependent inflammatory responses and pathogenic antibody production. Immunity. 2014;41:375&#x2013;388. doi: 10.1016/j.immuni.2014.08.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2014.08.011</ArticleId><ArticleId IdType="pubmed">25238095</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwasaki Y., Takeshima Y., Nakano M., Okubo M., Ota M., Suzuki A., Kochi Y., Okamura T., Endo T., Miki I., et al. Combined plasma metabolomic and transcriptomic analysis identify histidine as a biomarker and potential contributor in SLE pathogenesis. Rheumatology. 2022;62:905&#x2013;913. doi: 10.1093/rheumatology/keac338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keac338</ArticleId><ArticleId IdType="pubmed">35689621</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham R.R., Kozyrev S.V., Baechler E.C., Reddy M.V., Plenge R.M., Bauer J.W., Ortmann W.A., Koeuth T., Gonzalez Escribano M.F., Argentine, et al. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat. Genet. 2006;38:550&#x2013;555. doi: 10.1038/ng1782.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1782</ArticleId><ArticleId IdType="pubmed">16642019</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham R.R., Kyogoku C., Sigurdsson S., Vlasova I.A., Davies L.R., Baechler E.C., Plenge R.M., Koeuth T., Ortmann W.A., Hom G., et al. Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus. Proc. Natl. Acad. Sci. USA. 2007;104:6758&#x2013;6763. doi: 10.1073/pnas.0701266104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0701266104</ArticleId><ArticleId IdType="pmc">PMC1847749</ArticleId><ArticleId IdType="pubmed">17412832</ArticleId></ArticleIdList></Reference><Reference><Citation>Ban T., Kikuchi M., Sato G.R., Manabe A., Tagata N., Harita K., Nishiyama A., Nishimura K., Yoshimi R., Kirino Y., et al. Genetic and chemical inhibition of IRF5 suppresses pre-existing mouse lupus-like disease. Nat. Commun. 2021;12:4379. doi: 10.1038/s41467-021-24609-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-24609-4</ArticleId><ArticleId IdType="pmc">PMC8290003</ArticleId><ArticleId IdType="pubmed">34282144</ArticleId></ArticleIdList></Reference><Reference><Citation>Niewold T.B., Kelly J.A., Kariuki S.N., Franek B.S., Kumar A.A., Kaufman K.M., Thomas K., Walker D., Kamp S., Frost J.M., et al. IRF5 haplotypes demonstrate diverse serological associations which predict serum interferon alpha activity and explain the majority of the genetic association with systemic lupus erythematosus. Ann. Rheum. Dis. 2012;71:463&#x2013;468. doi: 10.1136/annrheumdis-2011-200463.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2011-200463</ArticleId><ArticleId IdType="pmc">PMC3307526</ArticleId><ArticleId IdType="pubmed">22088620</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou G., Zhou T., Xu N., Yin Z., Zhu X., Zhang Y., Cui Y., Ma J., Tang Y., Cheng Z., et al. Integrative functional genomics identifies SLE causal genetic variant in the IRF5 risk locus. Arthritis Rheumatol. 2022 doi: 10.1002/art.42390. ahead of print .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.42390</ArticleId><ArticleId IdType="pubmed">36245280</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinz L.X., Lee J., Kapoor U., Kartnig F., Sedlyarov V., Papakostas K., Cesar-Razquin A., Essletzbichler P., Goldmann U., Stefanovic A., et al. TASL is the SLC15A4-associated adaptor for IRF5 activation by TLR7-9. Nature. 2020;581:316&#x2013;322. doi: 10.1038/s41586-020-2282-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2282-0</ArticleId><ArticleId IdType="pmc">PMC7610944</ArticleId><ArticleId IdType="pubmed">32433612</ArticleId></ArticleIdList></Reference><Reference><Citation>Odhams C.A., Roberts A.L., Vester S.K., Duarte C.S.T., Beales C.T., Clarke A.J., Lindinger S., Daffern S.J., Zito A., Chen L., et al. Interferon inducible X-linked gene CXorf21 may contribute to sexual dimorphism in Systemic Lupus Erythematosus. Nat. Commun. 2019;10:2164. doi: 10.1038/s41467-019-10106-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-10106-2</ArticleId><ArticleId IdType="pmc">PMC6520347</ArticleId><ArticleId IdType="pubmed">31092820</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedl M., Yan J., Abraham C. IRF5 and IRF5 Disease-Risk Variants Increase Glycolysis and Human M1 Macrophage Polarization by Regulating Proximal Signaling and Akt2 Activation. Cell Rep. 2016;16:2442&#x2013;2455. doi: 10.1016/j.celrep.2016.07.060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2016.07.060</ArticleId><ArticleId IdType="pmc">PMC5165654</ArticleId><ArticleId IdType="pubmed">27545875</ArticleId></ArticleIdList></Reference><Reference><Citation>Albers G.J., Iwasaki J., McErlean P., Ogger P.P., Ghai P., Khoyratty T.E., Udalova I.A., Lloyd C.M., Byrne A.J. IRF5 regulates airway macrophage metabolic responses. Clin. Exp. Immunol. 2021;204:134&#x2013;143. doi: 10.1111/cei.13573.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cei.13573</ArticleId><ArticleId IdType="pmc">PMC7944363</ArticleId><ArticleId IdType="pubmed">33423291</ArticleId></ArticleIdList></Reference><Reference><Citation>Li D., Matta B., Song S., Nelson V., Diggins K., Simpfendorfer K.R., Gregersen P.K., Linsley P., Barnes B.J. IRF5 genetic risk variants drive myeloid-specific IRF5 hyperactivation and presymptomatic SLE. JCI Insight. 2020;5:e124020. doi: 10.1172/jci.insight.124020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.124020</ArticleId><ArticleId IdType="pmc">PMC7098722</ArticleId><ArticleId IdType="pubmed">31877114</ArticleId></ArticleIdList></Reference><Reference><Citation>Morand E.F., Furie R., Tanaka Y., Bruce I.N., Askanase A.D., Richez C., Bae S.C., Brohawn P.Z., Pineda L., Berglind A., et al. Trial of Anifrolumab in Active Systemic Lupus Erythematosus. N. Engl. J. Med. 2020;382:211&#x2013;221. doi: 10.1056/NEJMoa1912196.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1912196</ArticleId><ArticleId IdType="pubmed">31851795</ArticleId></ArticleIdList></Reference><Reference><Citation>Nln I., Fernandez-Ruiz R., Muskardin T.L.W., Paredes J.L., Blazer A.D., Tuminello S., Attur M., Iturrate E., Petrilli C.M., Abramson S.B., et al. Interferon pathway lupus risk alleles modulate risk of death from acute COVID-19. Transl. Res. 2022;244:47&#x2013;55. doi: 10.1016/j.trsl.2022.01.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trsl.2022.01.007</ArticleId><ArticleId IdType="pmc">PMC8802623</ArticleId><ArticleId IdType="pubmed">35114420</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>